PRDM2 and chronic myelogenous leukemia, BCR-ABL1 positive: Yet another report from our lab has observed that inactivation of RIZ1 gene by insertion/deletion polymorphism and promoter hypermethylation is associated with CML disease progression and imatinib resistance [61].